Early pre-clinical studies have demonstrated that AML cells are highly dependent on BCL-2 for survival, providing rationale for testing the highly selective oral BCL-2 inhibitor venetoclax [134,135,136], which also showed synergistic antileukemic activity with HMAs and chemotherapy in preclinical models [137,138,139]. This evidence concerns the gene BCL2 and acute myeloid leukemia.